Generic Luxiq® Launches
On January 15, 2013, Perrigo received final FDA approval for and commenced shipping the generic equivalent for GlaxoSmithKlines’s branded product, Luxiq® (betamethasone valerate) foam. Luxiq® had estimated total U.S. annual sales of approximately $30 million.
Betamethasone valerate foam is used to treat skin conditions of the scalp (such as psoriasis, seborrhea). Betamethasone valerate foam works by decreasing the swelling (inflammation), itching, and redness.